CORONA Remedies Peer Comparison

NSE: CORONA | BSE: 544644

₹2,024.00

₹30.50 (1.53%)

As on 09-Oct-2026IST

Market cap

₹12,380 Cr

Revenue (TTM)

₹1,479 Cr

P/E Ratio

62.2

P/B Ratio

15.3

Div. Yield

0.5 %

Edit

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	12,380	19,956	18,695	17,436	16,269
Revenue (₹ Cr)	1,479	1,682	2,287	2,570	3,230
Net Profit (₹ Cr)	198.55	273.51	678.07	735.15	666.92
Net Margin (%)	13.32	16.19	28.10	26.88	20.60
RoE (%)	30.33	11.15	19.73	19.16	18.75
Price to Earnings	62.20	67.12	28.10	23.72	25.27
Price-To-Book	15.34	7.43	5.09	3.96	4.03

Income Statement (₹ Cr)

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	1,479.07	1,682.47	2,287.33	2,569.77	3,229.67
Total Income	1,490.84	1,689.83	2,413.29	2,735.39	3,237.12
Total Expenditure	1,162.29	1,203.91	1,490.75	1,628.14	2,090.06
EBITDA	316.78	478.55	796.58	941.63	1,139.61
Depreciation	42.18	126.01	78.10	57.58	281.06
EBIT	274.60	352.55	718.48	884.05	858.55
Interest	7.66	52.11	0.88	7.69	190.64
Other Income	11.77	7.37	125.96	165.62	7.45
Exceptional Items	-19.10	12.16	0.00	-49.16	-17.24
Profit before Tax	259.61	319.96	843.56	992.82	658.12
Provision for Tax	61.06	46.45	165.49	257.67	-8.80
Profit after Tax	198.55	273.51	678.07	735.15	666.92

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	745.97	2,591.20	3,586.42	4,202.90	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	97.11	266.35	28.74	91.50	1,392.75
Current Liabilities	361.17	848.06	385.94	627.48	2,077.10
Total Liabilities	--	3,705.61	4,037.51	4,921.88	7,246.72

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	722.50	2,525.44	1,291.22	770.28	5,617.77
Current Assets	348.31	1,109.77	2,585.66	3,803.22	1,539.85
Total Assets	--	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	--	657.97	0.57	2.50	2,309.68
Net Current Assets	-12.86	261.71	2,199.72	3,175.74	-537.25
Contingent Liabilities	--	160.01	17.53	370.49	51.57

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	--	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	--	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	--	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	--	29.88	-105.52	-392.41	-145.00

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	--	11.43	24.97	23.39	14.47
ROE (%)	30.29	11.15	19.73	19.16	18.75
ROA (%)	32.97	7.80	18.69	14.95	9.26
EBIT Margin (%)	18.57	20.95	31.41	34.40	26.58
Net Margin (%)	13.32	16.19	28.10	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	18.16	27.91	15.01	10.69	9.59
EBIT Growth (%)	23.39	58.32	18.45	24.14	16.84
Net Profit Growth (%)	19.98	149.56	19.61	-9.09	62.68
EPS Growth (%)	28.60	-3.57	17.73	14.40	67.41
Book Value Growth (%)	--	9.67	26.75	-0.34	36.71

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	58.17	71.20	28.10	22.60	24.63
Price / Book Value	15.36	7.43	5.09	3.96	4.03
Dividend Yield (%)	0.49	0.06	0.33	1.97	0.00
EV/EBITDA	39.39	42.98	22.21	15.22	16.24
Market Cap (₹ Cr)	--	6,819.66	11,439.22	21,592.90	17,980.08

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.07	0.00	0.00	0.24
Short term debt to equity ratio	--	0.16	0.00	0.00	0.12
Current Ratio	0.96	1.31	6.70	6.06	0.74
Quick Ratio	0.62	0.88	5.59	5.31	0.53
Interest Coverage	34.89	7.14	959.59	130.11	4.45

	CORONA Remedies	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	9.84	30.84	36.10	7.07	21.07
Asset Turnover	2.46	0.48	0.63	0.52	0.45
Receivable days	--	113.81	121.68	26.06	63.88
Inventory Days	--	84.76	63.83	65.95	43.27
Payable days	--	101.94	108.28	81.01	151.85
Cash Conversion Cycle	--	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.